Alnylam lowers Amvuttra sales outlook amid waning demand, shares slide
read at Endpoints ↗EarningsNegative
Alnylam released its second‑quarter earnings, highlighting a challenging year for the biotech firm. The report showed continued pressure on its product portfolio.
The company cut its full‑year sales projection for Amvuttra, citing a shift in market demand that lowered expected revenue from the drug.
The guidance reduction triggered a drop in Alnylam’s stock price, adding to investor unease after earlier setbacks.
Analysts note that the weaker outlook for Amvuttra may affect the company’s overall financial performance and could influence future strategic decisions.
source
This writeup was produced by pharmadog from original reporting by Endpoints.
Original headline: “Alnylam cuts Amvuttra sales guidance as demand shifts, hurting stock”
read at Endpoints ↗81 words · retrieved Jul 30
comments(0)
5-min edit window · permanent after that